Rituximab Market Poised for Sustained Growth Through 2034, Driven by Multi-Indication Use and Biosimilar Expansion
核心洞察
Rituximab's broad indications across oncology and autoimmune diseases, including NHL, CLL, and rheumatoid arthritis (搜索), sustain a large diversified patient base despite biosimilar competition.
Global oncology sales for rituximab reached approximately $5.3 billion in 2018, with the market projected to maintain significant revenues through branded and biosimilar products through 2034.
Biosimilars have been available in the EU since 2013 and the US from 2018, contributing to price reductions and increased accessibility in emerging markets.
The global rituximab market is projected to experience sustained growth through 2034, underpinned by the drug's entrenched position across multiple oncology and autoimmune indications, according to a new report from ResearchAndMarkets.com (搜索). The analysis, titled "Rituximab Sales Forecast, and Market Size Analysis - 2034," provides a comprehensive assessment of the monoclonal antibody's commercial trajectory across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Rituximab, the first monoclonal antibody approved for cancer, remains integral to standard-of-care regimens in non-Hodgkin lymphoma (搜索) (NHL), chronic lymphocytic leukemia (搜索) (CLL), rheumatoid arthritis (搜索), and several other conditions. The report highlights that oncology continues to serve as the primary revenue driver, with global oncology sales reaching approximately $5.3 billion in 2018 before a modest decline to $5.0 billion in 2019.
Biosimilar Expansion and Market Accessibility
Biosimilar competition, which began in the European Union in 2013 and entered the United States market in 2018, has reshaped the commercial landscape for rituximab. Rather than eroding the market entirely, biosimilars have contributed to price reductions that expand patient access, particularly in emerging markets. The report notes that even after patent expiry, rituximab sustains significant global revenues through both branded and biosimilar products, reflecting the depth of physician confidence and treatment guideline preference built on extensive real-world data.
Combination Regimens and Emerging Clinical Data
The report underscores rituximab's continued relevance in evolving treatment paradigms, particularly its role in chemo-immunotherapy regimens and combinations with targeted agents and immunotherapies. A notable recent development cited in the analysis is a December 2025 clinical trial demonstrating that the BTK (搜索) inhibitor pirtobrutinib increased survival without disease progression compared to bendamustine plus rituximab, signaling ongoing innovation in rituximab-based combination strategies.
Approved and Potential Indications
The market analysis covers rituximab's approved indications, including chronic lymphocytic leukemia (搜索), follicular lymphoma (搜索), granulomatosis with polyangiitis (搜索), idiopathic thrombocytopenic purpura (搜索), lymphoproliferative disorders, and microscopic polyangiitis (搜索). The report also evaluates potential indications such as mantle-cell lymphoma (搜索), providing sales forecasts and market size projections for the 2020–2034 period across all 7MM markets.
Competitive Landscape and Strategic Outlook
The report provides a detailed competitive landscape assessment, covering both marketed therapies and late-stage emerging therapies that may pose competition to rituximab. It also examines pricing strategies, reimbursement landscapes, and geographical pricing variations. According to the analysis, companies are focusing on novel approaches to sustaining market dominance amid the emergence of new therapies, with the market predicted to grow due to strong adoption, increased prescriptions, and broader uptake across multiple indications.
The methodology underpinning the report draws on primary and secondary research, industry expert analysis, and data sourced from various databases and publications, ensuring a robust foundation for the market projections and competitive intelligence provided.